A three long non‑coding RNA signature to improve survival prediction in patients with Wilms' tumor
Affiliations: Department of Medicine, The Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang 315020, P.R. China, Department of Surgery, Cixi People's Hospital of Zhejiang, Ningbo, Zhejiang 315300, P.R. China
- Published online on: October 14, 2019 https://doi.org/10.3892/ol.2019.10990
Copyright: © Ren
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The prognostic significance of long non‑coding RNAs (lncRNAs) in Wilms' tumor (WT) remains unclear. The present study identified differential lncRNA expression patterns between WT and normal tissues; and evaluated the prognostic value of these lncRNAs. Multidimensional data from 136 samples were retrieved from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database. Computational data analyses were performed to detect survival‑associated molecular signatures. Kaplan‑Meier survival curves revealed the prognostic prediction values for three of these lncRNAs, namely DLGAP1 antisense RNA 2 (DLGAP1‑AS2), RP11‑93B14.6 and RP11554F20.1. Cox regression analysis revealed that the three‑lncRNA signature was significantly associated with patient survival (P<0.01). Functional enrichment analyses suggested that the target genes of these three lncRNAs may be involved in known cancer‑associated pathways. The present study revealed a three‑lncRNA signature consisting of DLGAP1‑AS2, RP11‑93B14.6 and RP11554F20.1 that may be used as a prognostic marker for patients with WT.